摘要
2023年7月,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六个学术组织联合发布了慢性冠心病(chronic coronary disease,CCD)管理指南。通过梳理最新的科学数据,指南再次强调了健康饮食、定期体育锻炼和戒烟对心血管健康的重要性,常规检测仅限于临床或功能状态发生变化的患者。在CCD的临床治疗方面,缩小了β受体阻滞剂(beta-blockers,BB)的应用范围,更新了3种药物的使用建议,包括钠-葡萄糖共转运蛋白2抑制剂(sodium glucose cotransporter 2inhibitors,SGLT2i)、胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂和贝派地酸。本文就《2023年AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠心病管理指南》进行解读。
In July 2023,six scientific organizations,including the American Heart Association(AHA)and theAmerican College of Cardiology(ACC),jointly released the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for themanagement of patients with chronic coronary disease.By reviewing the latest scientific data,the guideline reemphasizedthe importance of a healthy diet,regular physical activity and smoking cessation in cardiovascular health.Routine testingis limited to patients with changes in clinical or functional status.Regarding the clinical management of CCD,theguideline limited the use of beta-blockers(BB)and updated recommendations for the usage of three drugs,includingsodium-glucose cotransporter-2 inhibitors(SGLT2i),glucagon-like peptide-1(GLP-1)receptor agonists,and bempedoicacid.
作者
吴洋
李柏辰
丁宇坤
孙旭
WU Yang;LI Pochen;DING Yukun;SUN Xu(Department of Cardiology,the Dongzhimen Hospital of Beijing University of Chinese Medicine,Beijing 100700,P.R.China;Department of Pneumology,the Dongzhimen Hospital of Beijing University of Chinese Medicine,Beijing 100700,P.R.China;Department of Science and Technology,Beijing Fengtai Hospital of Integrative Medicine,Beijing 100072,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2024年第9期1094-1099,共6页
Chinese Journal of Evidence-based Medicine
基金
北京中医药大学“解码中医”课题(编号:2022-JYBJBZR-033)。
